Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure
PGE2
A Study on Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure
1 other identifier
observational
350
0 countries
N/A
Brief Summary
Acute-on-chronic liver failure (ACLF) is an ailment with high incidence of multiorgan failure (MOF) and consequent mortality. Systemic inflammation and susceptibility to infection are characteristic pathophysiological features. Prostaglandin E2 (PGE2) could subdue systemic inflammation and alleviate liver injury in mice model. However, there are no studies evaluating PGE2 as a predictor of early mortality.This study is designed to investigate whether plasma PGE2 and its receptors are associated with development of MOF and predict short-term mortality in patients with acute-on-chronic liver failure. By the way, we will also measure several other potential predictive factors (C-reactive protein,severe hyponatremia, Second infections,Diabetes mellitus,High density lipoprotein,interleukin-10,serum bile acids,ferritin,the neutrophil to lymphocyte ratio,soluable urokinase plasminogen activator receptor,vWF-Ag levels and FVIII-to-PC ratios).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2016
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 10, 2016
CompletedFirst Submitted
Initial submission to the registry
November 14, 2016
CompletedFirst Posted
Study publicly available on registry
November 16, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 10, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2018
CompletedJune 6, 2018
October 1, 2016
1 year
November 14, 2016
June 3, 2018
Conditions
Outcome Measures
Primary Outcomes (3)
all cause mortality
90 days
incidence of multiorgan failure
90 days
all cause mortality
30 days
Study Arms (1)
HC,CHB,AD,ACLF
HC healthy controls; CHB chronic hepatitis B; AD acute decompensated cirrhosis; ACLF acute-on-chronic liver failure.
Interventions
Eligibility Criteria
The cohorts will be selected from Provincial General Hospital
You may qualify if:
- Clinical diagnosis of acute-on-chronic liver failure according to Asian-Pacific Association for the Study of the Liver (APASL) diagnostic criteria
You may not qualify if:
- Hepatocellular carcinoma(HCC)
- Portal vein thrombosis
- Pregnancy
- Human immunodeficiency virus (HIV)
- Patients who had received immunomodulator,or cytotoxic/immunosuppressive therapy within at least the preceding 12 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Wang Y, Wu F, Chen C, Xu L, Lin W, Huang C, Yang Y, Wu S, Qi J, Cao H, Li G, Hong M, Zhu H. Soluble urokinase plasminogen activator receptor is associated with short-term mortality and enhanced reactive oxygen species production in acute-on-chronic liver failure. BMC Gastroenterol. 2021 Nov 17;21(1):429. doi: 10.1186/s12876-021-02006-x.
PMID: 34789156DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
November 14, 2016
First Posted
November 16, 2016
Study Start
October 10, 2016
Primary Completion
October 10, 2017
Study Completion
June 1, 2018
Last Updated
June 6, 2018
Record last verified: 2016-10